The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000573358p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
8/04/2026
Date registered
Help: Date registered
7/05/2026
Date last updated
Help: Date last updated
7/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluating the impact of a nurse-led clinic model of care on the symptom management of women prescribed adjuvant endocrine therapy for early breast cancer
Scientific title
Evaluating the impact of a nurse-led clinic model of care on the symptom management of women prescribed adjuvant endocrine therapy for early breast cancer: a quasi-experimental pilot study
Additional trial identifiers [1] 316910 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Breast cancer 341350 0
Condition category
Condition code
Cancer 337421 337421 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention in this study is a new nurse-led clinic (NLC) model of care designed to proactively monitor and manage symptoms for patients commencing adjuvant endocrine therapy (AET) for early, hormone receptor-positive breast cancer. This model replaces the current standard practice in Illawarra Shoalhaven Local Health District (ISLHD), where patients typically wait 6–8 weeks for a routine medical oncology follow-up appointment without formal interval monitoring.

The NLC intervention consists of the following components and processes:

• Electronic Symptom Monitoring:
Patients complete electronic patient-reported outcome (ePRO) symptom assessments at baseline (defined as prior to commencement of AET), and at 2, 4, 8, and 12 weeks following treatment initiation. The ePRO tool incorporates validated measures, including the Functional Assessment of Cancer Therapy – Endocrine Subscale (FACT-ES) and the Australasian Menopause Society Symptom Score Card, and is administered via a secure online platform.

• Proactive Nurse Review:
A breast cancer care nurse reviews each ePRO submission within 72 hours of completion.

• Targeted Clinical Support:
Clinical support is delivered primarily via telephone or email, with face-to-face consultation arranged if clinically indicated. Following each ePRO review, patients may receive nurse-initiated contact where symptoms warrant intervention. The frequency and duration of contact are individualised based on patient need, typically ranging from brief (5–10 minute) telephone consultations to longer discussions (up to approximately 30 minutes) when more complex symptom management is required. Contact generally occurs at each assessment timepoint where symptoms are identified, rather than at fixed intervals.

Support strategies provided by the nurse may include:

Education and advice: Patients may receive a combination of written and digital resources, including patient information sheets, website links, and webinars/podcasts. These materials are not developed specifically for this study but are sourced from established organisations such as Breast Cancer Network Australia and the Australasian Menopause Society, as well as standard clinical education resources used within ISLHD.

Symptom management guidance: Tailored advice is provided based on reported symptoms (e.g., management of menopausal symptoms, musculoskeletal pain, or sexual dysfunction).

Facilitation of referrals: The nurse may coordinate referrals to internal ISLHD services (e.g., Menopause Service, psychology, lymphoedema physiotherapy) by initiating referral processes, liaising with relevant departments, and assisting with appointment coordination where required. Referrals to external services (e.g., general practitioners for chronic disease management plans) may also be recommended, with guidance provided to the patient on how to access these services.

Escalation of care: Where symptoms fall outside the nurse’s scope of practice or are clinically concerning, the nurse may facilitate earlier review by a medical oncologist.

• Adherence to the intervention is monitored through:
Completion rates of scheduled ePRO assessments recorded within REDCap.
Documentation of nurse review and patient contact within the platform.
Nurse-completed activity time logs capturing all intervention-related activities (e.g., review time, patient contact, referrals).
Intervention code [1] 333644 0
Treatment: Other
Description of the comparator or control
The comparator for this study is a retrospective historical control cohort consisting of patients who received the standard of care in ISLHD prior to the implementation of the NLC model. Under this standard care, patients prescribed AET typically attend a routine follow-up appointment with a medical oncologist approximately 6–8 weeks after commencing medication to discuss side effects and potential management strategies. While patients are advised they can contact the cancer clinic with concerns, there is no proactive, structured symptom monitoring during the initial treatment phase. This cohort will be identified through a systematic clinical audit of medical records and oncology prescribing software for the 12-month period immediately preceding the study. Data extracted from this group, including rates of treatment cessation, therapy switching, and healthcare utilisation will serve as a comparison against the prospective intervention group.
Control group
Historical

Outcomes
Primary outcome [1] 345015 0
Composite change in patient-reported symptoms and side-effects associated with adjuvant endocrine therapy (AET).
Timepoint [1] 345015 0
Baseline (prior to AET commencement) 2 weeks post-treatment initiation 4 weeks post-treatment initiation 8 weeks post-treatment initiation 12 weeks post-treatment initiation
Primary outcome [2] 345016 0
Rate of permanent discontinuation of AET within the early treatment period (initial 12 weeks).
Timepoint [2] 345016 0
Assessed cumulatively within 12 weeks post-treatment initiation (prospective cohort). Equivalent 12-week period following initiation in retrospective cohort.
Primary outcome [3] 345021 0
Rate of switching between AET agents due to intolerance or side effects.
Timepoint [3] 345021 0
Assessed cumulatively within 12 weeks post-treatment initiation (prospective cohort). Equivalent 12-week period in retrospective cohort.
Secondary outcome [1] 460148 0
Study recruitment rate.
Timepoint [1] 460148 0
Calculated at completion of participant recruitment period.
Secondary outcome [2] 460150 0
Completion rate of scheduled ePRO symptom assessments.
Timepoint [2] 460150 0
Evaluated across the full 12-week intervention period.
Secondary outcome [3] 460152 0
Composite measure of patient acceptability and satisfaction with the nurse-led clinic (NLC) model.
Timepoint [3] 460152 0
At completion of participation (approximately 12 weeks post-treatment initiation).
Secondary outcome [4] 460155 0
Number of routine 6–8 week oncology follow-up appointments avoided.
Timepoint [4] 460155 0
Assessed at study completion following the 12-week follow-up period.
Secondary outcome [5] 460156 0
Medication adherence behaviour among patients commencing AET.
Timepoint [5] 460156 0
2 weeks post-treatment initiation 8 weeks post-treatment initiation 12 weeks post-treatment initiation
Secondary outcome [6] 460157 0
Net healthcare resource impact per patient of the NLC model compared with standard care.
Timepoint [6] 460157 0
Calculated at completion of study follow-up (after 12 weeks per participant).

Eligibility
Key inclusion criteria
Participants will be recruited into three cohorts: breast cancer care nurses, a prospective patient intervention cohort, and a retrospective historical control cohort.

Prospective patient cohort (intervention group):

Aged 18 years or older.
Diagnosed with primary early-stage hormone receptor–positive breast cancer.
Prescribed and consenting to commence AET.
Able to read and understand English.
Provide written informed consent to participate.

Retrospective patient cohort (historical control cohort):

Aged 18 years or older.
Diagnosed with primary early-stage hormone receptor–positive breast cancer.
Commenced AET within the 12 months preceding study commencement.
Have complete medical records sufficient to determine treatment adherence and healthcare utilisation during the first 12 weeks of therapy.

Nurse cohort:

Registered breast cancer care nurse employed within Illawarra Shoalhaven Local Health District (ISLHD).
Currently involved in monitoring patients with early hormone receptor–positive breast cancer.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Prospective patient cohort (intervention group):

Hormone receptor–negative breast cancer.
Advanced or metastatic breast cancer.
Prescribed combined treatment with adjuvant endocrine therapy and a CDK4/6 inhibitor.

Retrospective patient cohort (historical control group):

Hormone receptor–negative breast cancer.
Advanced or metastatic breast cancer.
Prescribed combined treatment with adjuvant endocrine therapy and a CDK4/6 inhibitor.
Previously completed AET electronic patient-reported outcome (ePRO) assessments as part of quality improvement testing.
Medical records lacking sufficient information to determine adherence or healthcare utilisation outcomes.

Nurse cohort:

Breast care nurses exclusively managing patients with advanced or metastatic breast cancer.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Data will be analysed using descriptive and comparative statistics to evaluate feasibility, acceptability, clinical outcomes, and preliminary service impacts of a nurse-led clinic model of care. Baseline characteristics will be summarised using means and standard deviations or medians and interquartile ranges for continuous variables, and frequencies and percentages for categorical variables. Feasibility outcomes will include recruitment and assessment completion rates. Acceptability questionnaire responses will be summarised descriptively. Longitudinal patient-reported symptom scores and medication adherence (MARS-5) within the intervention cohort will be summarised at each timepoint and explored using repeated-measures analyses where appropriate. Treatment cessation and therapy switching rates will be compared between intervention and historical control cohorts using chi-square or Fisher’s exact tests, with effect sizes reported. Healthcare utilisation and cost outcomes will be analysed descriptively. Missing data will be handled using available-case analysis. As a pilot study, analyses will focus on estimating trends to inform future trials rather than definitive hypothesis testing.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321505 0
Government body
Name [1] 321505 0
Illawarra Shoalhaven Local Health District
Country [1] 321505 0
Australia
Primary sponsor type
Government body
Name
Illawarra Shoalhaven Local Health District
Address
Country
Australia
Secondary sponsor category [1] 324380 0
None
Name [1] 324380 0
Address [1] 324380 0
Country [1] 324380 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320037 0
Greater Western Human Research Ethics Committee
Ethics committee address [1] 320037 0
Ethics committee country [1] 320037 0
Australia
Date submitted for ethics approval [1] 320037 0
23/03/2026
Approval date [1] 320037 0
Ethics approval number [1] 320037 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149226 0
Ms Lisa Cook
Address 149226 0
Wollongong Hospital, Locked Mail Bag 8808, South Coast Mail Centre, NSW 2521
Country 149226 0
Australia
Phone 149226 0
+61 2 4253 4389
Fax 149226 0
Email 149226 0
Contact person for public queries
Name 149227 0
Lisa Cook
Address 149227 0
Wollongong Hospital, Locked Mail Bag 8808, South Coast Mail Centre, NSW 2521
Country 149227 0
Australia
Phone 149227 0
+61 2 4253 4389
Fax 149227 0
Email 149227 0
Contact person for scientific queries
Name 149228 0
Lisa Cook
Address 149228 0
Wollongong Hospital, Locked Mail Bag 8808, South Coast Mail Centre, NSW 2521
Country 149228 0
Australia
Phone 149228 0
+61 2 4253 4389
Fax 149228 0
Email 149228 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Consent is only being sought for use of patient data in this specific study.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.